What's Happening?
Nature has opened a new Collection for submissions focusing on microphysiological systems (MPSs), which are transforming the modeling of human physiology and disease mechanisms. This initiative is supported by the FDA Modernization Act 3.0, which encourages
the use of alternative methods to reduce reliance on animal models. The Collection invites manuscripts that highlight engineering advances, high-throughput evaluation, and translational applications of next-generation MPSs, such as 3D culture systems and organs-on-chips. Submissions are open to all authors, provided they align with the Collection's scope and the editorial policies of participating journals.
Why It's Important?
The focus on microphysiological systems represents a significant shift in biomedical research, offering more accurate and ethical alternatives to traditional animal testing. This can lead to faster and more reliable drug development processes, potentially reducing costs and time to market for new therapies. The FDA's support underscores the importance of these systems in advancing medical research and improving clinical outcomes. By encouraging submissions, Nature is fostering innovation and collaboration in this field, which could lead to breakthroughs in understanding complex diseases and developing personalized medicine.
What's Next?
As the Collection gains traction, it is expected that more researchers will contribute to the development of MPSs, leading to a broader acceptance and implementation of these systems in research and clinical settings. The ongoing support from regulatory bodies like the FDA may also encourage more funding and investment in this area, accelerating the pace of innovation. Researchers and institutions may need to adapt to new methodologies and technologies, which could reshape the landscape of biomedical research and education.
